Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15208MR)

This product GTTS-WQ15208MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13&TNFSF13B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001198622.2; NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8741; 10673
UniProt ID Q2QBA2; Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15208MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4902MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ13533MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRX-003
GTTS-WQ4970MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ2636MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ14103MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ446MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ5364MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ3521MR IVTScrip™ mRNA-Anti-APP, BART(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BART
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW